Get the Stockscreener App
2.17
1.36%
-0.03
Pre-market:
2.09
-0.08
-3.69%
Lyell Immunopharma Inc stock is currently priced at $2.17, with a 24-hour trading volume of 346.25K.
It has seen a -1.36% decreased in the last 24 hours and a +11.86% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.29 pivot point. If it approaches the $2.06 support level, significant changes may occur.
Previous Close:
$2.20
Open:
$2.19
24h Volume:
346.25K
Market Cap:
$553.21M
Revenue:
$130.00K
Net Income/Loss:
$-234.63M
P/E Ratio:
-2.5833
EPS:
-0.84
Net Cash Flow:
$-166.38M
1W Performance:
-2.69%
1M Performance:
+11.86%
6M Performance:
+33.13%
1Y Performance:
+14.81%
1D Range:
$2.11
$2.21
52W Range:
$1.32
$3.97
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Name
Lyell Immunopharma Inc
Sector
Industry
Phone
650 695 0677
Address
400 East Jamie Court, Suite 301, South San Francisco
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-11-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-17-22 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | BofA Securities | Buy |
| Jul-12-21 | Initiated | Goldman | Buy |
| Jul-12-21 | Initiated | JP Morgan | Overweight |
| Jul-12-21 | Initiated | Morgan Stanley | Overweight |
View All
Lyell Immunopharma Inc Stock (LYEL) Latest News
Live Nation Entertainment, Groupon And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Benzinga
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Argan Reports Upbeat Earnings, Joins Coupang And Other Big Stocks Moving Higher On Friday
Benzinga
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday
Benzinga
Lyell Immunopharma (LYEL) Is Up 28.45% in One Week: What You Should Know
Zacks Investment Research
Lyell Immunopharma Inc Stock (LYEL) Financials Data
Lyell Immunopharma Inc (LYEL) Revenue 2024
LYEL reported a revenue (TTM) of $130.00 thousand for the quarter ending December 31, 2023, a -99.85% decline year-over-year.
Lyell Immunopharma Inc (LYEL) Net Income 2024
LYEL net income (TTM) was -$234.63 million for the quarter ending December 31, 2023, a -28.13% decrease year-over-year.
Lyell Immunopharma Inc (LYEL) Cash Flow 2024
LYEL recorded a free cash flow (TTM) of -$166.38 million for the quarter ending December 31, 2023, a +14.16% increase year-over-year.
Lyell Immunopharma Inc (LYEL) Earnings per Share 2024
LYEL earnings per share (TTM) was -$0.93 for the quarter ending December 31, 2023, a -25.68% decline year-over-year.
About Lyell Immunopharma Inc
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845 for multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
1.53%
3.38%
Cap:
|
Volume (24h):